For larger generic players such as Teva Pharmaceutical Industries Ltd. ( TEVA ) and Mylan Pharmaceuticals Inc. ( MYL ), the policy changes effectively could knock some costs down. Controlling overhead for generic companies is a key to bottom-line performance as margins are thinner in the sector. For Teva this is particularly important given its efforts at cutting debt and restructuring, including putting 14,000 employees on the street this year. Teva did not respond to TheStreet's request for comment. Mylan spokeswoman Lauren Kashtan told TheStreet, "Mylan has been a leader in fighting REMS abuse to expand patient access to generic drugs for more than a decade. We applaud FDA's efforts today to help mitigate one area of the abuse. To help patients unlock savings from generics that are currently being blocked by some brand companies, we need Congress' help in passing the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act."